Clinical Liver Disease Debuts New Series of Supplement Issues
By Ann Haran, AASLD Staff
Clinical Liver Disease (CLD) recently launched the first installment of a new series of thematic supplement
issues. Focusing on pathology, the supplement will join three newly commissioned
articles with relevant repurposed content from past and future issues of CLD. In
order to keep CLD as timely as possible, the editorial team felt it was
important to continually regroup and augment materials for the reader’s benefit.
“Other issues of CLD
focus on a specific disease topic,” explains supplement Guest Editor Raouf E.
Nakhleh, MD, FCAP, who also serves on CLD’s Editorial Board. “The supplement
issues will not be grouped by disease topic; rather, they are intended to help
as a reference point. We felt it was necessary to have supplements for the sake
of completeness.” Editor-in-Chief Michael R. Lucey, MD, adds “having supplements
allows us to maintain frequency of publication, and also allows us to address
topics that would not get a full issue of their own but appear in various
issues.
Having a pathology supplement also allowed us to publish three valuable
articles describing normal anatomy and histology of the liver that otherwise
would not have been written.” While the supplement issues do provide an
opportunity for new materials to be written, they will also gather previously
published articles under a different thematic title. As new issues of the
journal are published, articles from these new issues will be used to populate
previously published supplements.
The pathology supplement begins with an article on the basic anatomy of the
liver, then goes on to explain its
histology. “We wanted readers to be able to comprehend the normal structures and
tools used in pathology,” explains Dr. Nakhleh, “so that any hepatologist or
trainee with an interest in liver disease will be able to develop a basic
understanding of what we, as pathologists, do every day.” Dr. Lucey points out
that trainees often find it challenging to understand pathology, and also
expects mid-level providers, such as nurse practitioners and physician
assistants, who do not have a great deal of training in pathology to find the
supplement quite useful. The supplement may also provide a refresher for people
who have been trained in pathology, but do not often have the opportunity to
practice that knowledge.
With future supplements being planned in other topics, such as surgery of the
liver and a supplement in Spanish, the editors are continuously brainstorming
ways to present users with complete, timely information in the most organized
manner possible. “We want enough information in this journal so that the reader
can go to one page and find exactly what he is looking for,” emphasizes Dr.
Nakhleh. “Ultimately, our goal is to cover everything in hepatology in a way
that will allow users to understand how medicine works in relation to liver
disease.”
Clinical Liver Disease
Normal liver anatomy (pages S1–S3)
Lena Sibulesky
Article first published online: 29 MAR 2013 | DOI: 10.1002/cld.124
Abstract
Full Article (HTML)
PDF(662K)
References
Request Permissions
Microscopic anatomy of the liver (pages S4–S7)
Murli Krishna
Article first published online: 29 MAR 2013 | DOI: 10.1002/cld.147
Abstract
Full Article (HTML)
PDF(1198K)
References
Request Permissions
Role of special stains in diagnostic liver pathology (pages S8–S10)
Murli Krishna
Article first published online: 29 MAR 2013 | DOI: 10.1002/cld.148
Abstract
Full Article (HTML)
PDF(1152K)
References
Request Permissions
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment